Cambridge Nucleomics Ltd
Cambridge Nucleomics Ltd
#13135667 • Active
Founded: 15/01/2021
Industries: Research and experimental development on biotechnology
Location: Oakham
Financial Snapshot
Last accounts made up to 30 June 2024
Next accounts due 31 March 2026 (10 months)
Cash in Bank £10,387
↓ -75%
Total Liabilities £14,491
↑ 245%
Employees 2
↑ 0%
Directors
Name | Role | Appointed ↓ | Nationality | Age |
|---|---|---|---|---|
| Max Zhu | Company Director | 06/03/2025 | Chinese | 43 years |
| John Mark Yeomans | Company Director | 03/03/2025 | British | 68 years |
| Hendrik Friedrich Peter Runge | Ceo | 17/10/2022 | German | 34 years |
| Ulrich Felix Keyser | Professor | 17/05/2021 | German | 50 years |
Role:
Company Director
Appointed:
06/03/2025
Nationality:
Chinese
Age:
43 years
Role:
Company Director
Appointed:
03/03/2025
Nationality:
British
Age:
68 years
Role:
Ceo
Appointed:
17/10/2022
Nationality:
German
Age:
34 years
Role:
Professor
Appointed:
17/05/2021
Nationality:
German
Age:
50 years
People with Significant Control
| Name | Nature of Control | Notified On | Nationality |
|---|---|---|---|
| Hendrik Friedrich Peter Runge | Ownership Of Shares 50 To 75 Percent, Voting Rights 50 To 75 Percent | 28/10/2022 | German |
| Ulrich Felix Keyser | Ownership Of Shares 25 To 50 Percent, Voting Rights 25 To 50 Percent | 15/01/2021 | German |
Hendrik Friedrich Peter Runge
Nature of Control:
Ownership Of Shares 50 To 75 Percent, Voting Rights 50 To 75 Percent
Notified On:
28/10/2022
Nationality:
German
Ulrich Felix Keyser
Nature of Control:
Ownership Of Shares 25 To 50 Percent, Voting Rights 25 To 50 Percent
Notified On:
15/01/2021
Nationality:
German
Financial Accounts
| Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|
| Income Statement | |||
| Turnover | |||
| Export Revenue | |||
| Sales | |||
| Other Operating Income | |||
| Other Operating Items | |||
| Cost of Sales | |||
| Raw Materials & Consumables | |||
| Gross Profit | |||
| Admin Expenses | |||
| Other Operating Charges | |||
| Depreciation | |||
| R&D Expenses | |||
| Operating Profit | |||
| EBITDA | |||
| Financial Revenue | |||
| Financial Expenses | |||
| Financial Profit/Loss | |||
| Interest Paid | |||
| Extraordinary Revenue | |||
| Extraordinary Expenses | |||
| Net Extraordinary Items | |||
| Pre-Tax Profit | |||
| Tax | |||
| Profit After Tax | |||
| Retained Profit | |||
| Balance Sheet | |||
| Non-Current Assets | |||
| Intangible Assets | |||
| Tangible Fixed Assets | |||
| Other Non-Current Assets | |||
| Current Assets | |||
| Stock | |||
| Debtors | |||
| Cash in Hand | |||
| Other Current Assets | |||
| Called Up Share Capital | |||
| P&L Account Reserve | |||
| Shareholder Funds | |||
| Other Shareholder Funds | |||
| Provisions | |||
| Long Term Debt | |||
| Creditors (> 1 year) | |||
| Other Non-Current Liabilities | |||
| Short Term Debt | |||
| Creditors | |||
| Creditors (< 1 year) | |||
| Other Current Liabilities | |||
| Key Metrics | |||
| Net Assets | |||
| Net Current Assets | |||
| Total Assets Less Current Liabilities | |||
| Working Capital | |||
| Enterprise Value | |||
| Added Value | |||
| Cashflow Before D&A | |||
| Other Information | |||
| Staff Costs | |||
| Number of Employees | |||
Charges
No charges registered
Properties
No property information available
Grants
No grant information available
Group Structure
No group structure information available
Government Council Contracts Beta
No council contracts found
Company Filings
| Date | Category | Description | Document |
|---|---|---|---|
| 25/03/2025 | Accounts | Accounts With Accounts Type Total Exemption Full | View (8 pages) |
| 13/03/2025 | Incorporation | Memorandum Articles | View (54 pages) |
| 13/03/2025 | Capital | Capital Allotment Shares | View (3 pages) |
| 13/03/2025 | Resolution | Resolution | View (4 pages) |
| 12/03/2025 | Capital | Capital Variation Of Rights Attached To Shares | View (2 pages) |
| 12/03/2025 | Capital | Capital Allotment Shares | View (3 pages) |
| 12/03/2025 | Capital | Capital Allotment Shares | View (3 pages) |